Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance of 3,911,385 Common Shares at a price of CAD $0.12. As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a...
2025-07-04 8:20 AM EDT
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial
Calgary, Alberta--(Newsfile Corp. - July 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous Angiogenic Cell Precursors-A Molecular Strategy for The Treatment of Heart Failure: Response to BioCardia's Cardiamp HF Trial. Recent research has revealed the importance of choosing the right patients and the right type of stem cell to effectively treat inflammatory heart disease. Many...
2025-07-03 10:16 AM EDT
Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
Calgary, Alberta--(Newsfile Corp. - July 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company focused on autologous stem cell therapies for cardiovascular diseases, is pleased to announce that Florida Senate Bill 1768 has officially become law on July 1, which enables the commercial sales of VesCell (ACP-01) in the state of Florida. The Company is on track to offer first commercial treatments by Q4 2025 and now projects sales of $22,500,000...
2025-07-02 3:00 AM EDT
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen is an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. Clinically, ACP-01 has been observed to reverse vascular dementia for more...
2025-06-27 11:54 AM EDT
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at $0.10. Each Unit will consist of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date....
2025-06-26 9:00 AM EDT
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to the approval of the TSXV Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities...
2025-06-17 8:41 AM EDT
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for cardiovascular diseases, is presenting its groundbreaking clinical trial results and regenerative medicine innovations today at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) 2025 World Congress in Freiburg, Germany. Hemostemix's presentation highlights the...
2025-05-20 9:00 AM EDT
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the previously announced USD $336,500 non-brokered private placement, issuing 1,634,466 Common Shares at CAD $0.295 each to CytoImmune Therapeutics LLC, following the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. Per Policy 4.1., Cytoimmune...
2025-05-12 9:00 AM EDT
Hemostemix at Invest Stuttgart
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands of investors, financial professionals, and innovators, offering a dynamic platform for Hemostemix to showcase its advancements and connect with potential...
2025-05-08 9:12 AM EDT
Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio
Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest. PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences. The engagement underscores Hemostemix's commitment to expanding its intellectual...
2025-04-23 11:53 AM EDT
Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, pitched the treatment of Vascular Dementia with ACP-01 to Wall Street. "The specificity of ACP-01 in promotion of angiogenesis, the molecular up-regulation of brain neurotrophic factors, and specific chemokines, strongly suggest ACP-01...
2025-03-17 10:28 AM EDT
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients...
2025-03-06 7:30 AM EST
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announces the sale of 15 ACP-01 Therapy...
2025-03-05 7:45 AM EST
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect...
2025-02-20 6:05 AM EST
Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect...
2025-02-19 3:24 PM EST
Hemostemix Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investment Regulatory Organization ("CIRO"), it is issuing this news release to clarify and provide additional information regarding its previous announcement dated February 10, 2025. On February 10, 2025, Hemostemix announced the engagement of Proconsul Capital Ltd. to provide investor relations...
2025-02-13 8:09 PM EST
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification from the International Air Transport Association (IATA). This milestone reinforces Puerto Rico's status as a global leader in the logistics of biologics and pharmaceutical products. The CEIV Pharma Certification ensures the highest standards in the handling, storage, and transportation of...
2025-02-11 9:43 AM EST
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital Ltd. ("ProConsul"), to provide investment marketing consulting services (the "Services") commencing February 6th, 2025. In consideration for the Services, the Company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the stock options...
2025-02-10 10:48 AM EST
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares
Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at today's closing price of $0.295 ($336,500 / $0.69789 = $482,167.68) (1,634,466 Common Shares), subject to the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. "The Hemostemix technology...
2025-02-04 5:16 PM EST
Hemostemix Expands to the Dominican Republic
Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company brings its revolutionary ACP-01 therapy back to the Dominican Republic. Hemostemix has posted an update on Social Media, sharing an inside look at its latest initiative in the Dominican Republic, with a team of cardiologists who have the capacity to treat 110 patients per month. This team of...
2025-02-03 12:57 PM EST